Brevibloc Injection
Product Images NDC 0404-9825

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Brevibloc (NDC 0404-9825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

Illustration of a two-port INTRAVIA bag showing a medication port designed for withdrawing the initial bolus and a delivery port for intravenous administration. The diagram labels both ports and focuses on the bag's functional components.*

FDA Label Image

Formula1.jpg (Formula1)

Chemical structure diagram showing the molecular formula of esmolol hydrochloride, the active ingredient in Brevibloc injection 10 mg/mL by Henry Schein, Inc.*

FDA Label Image

Label1.jpg (Label1)

Label for Brevibloc (esmolol hydrochloride) injection, 10 mg/mL, 10 mL vial, for intravenous use. The label indicates the product is ready-to-use, iso-osmotic with no preservatives, and includes storage instructions at 25C (77F) with permitted excursions. Manufacturer and packager information is Henry Schein, Inc, located in Bastian, VA.*

FDA Label Image

Table1.jpg (Table1)

A table titled 'Table 1 Step-Wise Dosing' showing a four-step dosing regimen for a medication. Each step details an action involving optional loading doses and subsequent dosages expressed in mcg per kg per minute over specified time intervals, progressively increasing the dosage if necessary.*

FDA Label Image

Table2 (Table2)

A table titled 'BREVIBLOC Injection Presentations' displays three formulations of Brevibloc (esmolol hydrochloride) injection. It lists: Brevibloc Premixed Injection at 10 mg/mL in a 250 mL bag (total dose 2500 mg); Brevibloc Double Strength Premixed Injection at 20 mg/mL in a 100 mL bag (total dose 2000 mg); and Brevibloc Injection at 10 mg/mL in a 10 mL vial (total dose 100 mg).*

FDA Label Image

Table3 (Table3)

Table listing clinical trial adverse reactions for Brevibloc (esmolol hydrochloride) with frequency of 3% or greater. Reactions are grouped by system organ class including vascular disorders (hypotension at 25%), general disorders (infusion site reactions at 8%), gastrointestinal disorders (nausea at 7%), and nervous system disorders (dizziness and somnolence at 3% each). Additional notes mention resolution of hypotension during or after infusion.*

FDA Label Image

Table4.jpg (Table4)

A data table titled 'Table 4 BREVIBLOC Injection Formulations' listing the ingredients and concentrations for three formulations of Brevibloc (esmolol hydrochloride) injection: Brevibloc Premixed Injection (10 mg/mL, 250 mL volume), Brevibloc Double Strength Premixed Injection (20 mg/mL, 100 mL volume), and Brevibloc Injection (10 mg/mL, 10 mL volume). It includes Esmolol Hydrochloride, Sodium Chloride, Water for Injection, Sodium Acetate Trihydrate, Glacial Acetic Acid, and notes on pH adjustment with Sodium Hydroxide and Hydrochloric Acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.